Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Objective To elucidate the common and distinct clinical features of immune-mediated necrotising myopathy (IMNM), also known as necrotising autoimmune myopathy associated with autoantibodies against ...

In our cohort, 6 of 7 patients with isolated anti-Ku presented typical immune-mediated necrotizing myopathy (IMNM)-like pathological features with predominantly necrotic muscle fibre and CD68 + ...

LAG-3 is an inhibitory receptor expressed on the surface of activated T lymphocytes, which has been shown to interfere with the binding of major histocompatibility complex II (MHCII) to the TCR 85 and ...

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced a license agreement ...

Discover Cabaletta Bio's promising CAR T-cell therapy for autoimmune diseases! Durable efficacy, FDA support, and clinical potential make this attractive.

Clinically meaningful drug-free responses were observed in 3 of 4 refractory patients with immune-mediated necrotizing myopathy (IMNM), which are consistent with published data.

Clinically meaningful drug-free responses were observed in 3 of 4 refractory patients with immune-mediated necrotizing myopathy (IMNM), which are consistent with published data.